Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET BOSTON, Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a r ...

Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024 BOSTON, Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available o ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) ended the latest trading session at $0.37, reflecting a +0.3% adjustment from the previous day's close, outperforming the S&P 500's daily loss of 0.5% [1] - The company's stock has increased by 12.72% over the past month, significantly surpassing the Medical sector's gain of 0.74% and the S&P 500's gain of 0.1% [6] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$0.08 per share in the upcoming earnings report, indicating a year-over-year growth of 11.11% [2] - For the entire fiscal year, Zacks Consensus Estimates predict earnings of -$0.30 per share and revenue of $175.18 million, reflecting changes of +23.08% and -30.33% from the previous year, respectively [7] Analyst Estimates - Recent changes to analyst estimates for Ginkgo Bioworks suggest a positive outlook, as these adjustments often reflect shifting short-term business dynamics [3] - The Zacks Rank system indicates that Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [10] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 81, placing it in the top 33% of over 250 industries [4]

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $0.30, moving +0.6% from the previous trading session. This change outpaced the S&P 500's 2.32% loss on the day. Elsewhere, the Dow lost 1.25%, while the tech-heavy Nasdaq lost 3.64%. Prior to today's trading, shares of the company had lost 5.9% over the past month. This has lagged the Medical sector's gain of 0.32% and the S&P 500's gain of 1.79% in that time. Market participants will be closely following the financial results of Gi ...

Group 1 - Purcell & Lefkowitz LLP is investigating Ginkgo Bioworks Holdings, Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [3] - The investigation is being conducted on behalf of Ginkgo's shareholders [3] - Shareholders can obtain additional information regarding their rights and options at no cost [1][2]

Given that analysts also expect Ginkgo's top line to rebound sharply in 2025, I believe that risk-tolerant growth investors who are looking for a biotech play can consider buying a small amount of DNA stock at this point. Meanwhile, on April 10, Ginkgo and Novo Nordisk (NYSE:NVO) disclosed they had expanded their strategic partnership. Under the five-year deal, the firms will seek "to improve the manufacturing of Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity medicatio ...

According to a press release, Ginkgo aims to "develop and optimize" a microbial strain for a secondary metabolite under Syngenta's pipeline. On a scientific basis, Syngenta's research team has identified the biological solution as a high-potential asset. Financially, the partnership also offers a cost-effective approach toward large-scale production of the targeted metabolite. The agricultural technology (or agritech) market is sizable, having reached a valuation of $23.5 billion in 2022. Further, Zion Mark ...

BASEL, Switzerland and BOSTON, July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology. Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can ...

A recovery plan is underway, but it isn't a slam dunk. To say that Ginkgo Bioworks' (DNA -10.03%) stock is in a bit of a rough patch doesn't quite capture it. With the price of its shares down by 81% in 2024 alone, many investors are likely wishing they had walked out the door months ago. But with the biotech's ambitious vision for highly automated biopharma manufacturing still unrealized, there may yet be rewards waiting for those who hold on for a bit longer. Or shareholders could just experience even mor ...

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.30 per share and a revenue of $175. ...